Product Summary
The study is given to the analysis of the latest growth trends and prospects for the Alzheimer’s Therapeutics market.
The section “ Alzheimer’s Therapeutics Market“ includes an examination of the situation in major sections of the Alzheimer’s Therapeutics market. The markets in European Union countries are examined in more detail, giving a timeline of financial results reported by major 3PL providers in 2017.
Browse full report: https://www.credenceresearch.com/report/alzeimers-therapeutic-market
Market Insight:
Alzheimer’s disease is a progressive and currently incurable disease, and potential or supportive treatments have only emerged in the last decade. However, the currently available treatments are lacking in terms of efficacy or target-specificity. There are two types of drug classes used in treatment of Alzheimer’s disease, acetylcholinesterase (ACE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonist. ACE inhibitors constitute of galantamine hydrochloride, donepezil hydrochloride and rivastigmine; NMDA receptor antagonist includes mematidine hydrochloride. Since the discovery of what plaques and tangles comprised in Alzheimer’s – amyloid β (Aβ) peptide and hyperphosphorylated tau (p-tau) protein respectively. An immense research and development has been carried out to develop therapeutics which can limit the rate of synthesis, reduce the toxicity or clear these factors from the brain. However, these attempts have been largely unsuccessful. Hence, considering the continuously rising Alzheimer prevalent population, as well as limited drugs available for treatment, Alzheimer’s disease presents a lucrative opportunity for an effective disease-modifying therapy to enter the market.
Pipeline Analysis
The phase III drugs included in the pipeline analysis are ENA713 (Novartis Pharmaceuticals), Flutemetamol (18F) (GE Healthcare), LY450139 (Eli Lilly and Company), Dimebon (Medivation, Inc. & Pfizer, Inc.), and Aripiprazole/ BMS-337039 (Otsuka Pharmaceutical, Inc.). The overall pipeline for Alzeihmer’s is still very much dominated by small molecule drugs. However, there is still a considerable number of biologics in the pipeline with total 86 molecules, represented across all stages of development. According to market experts, the diversity of the several molecule types in the biologic group shows a certain level of innovation, with newer avenues being explored in accounts of recent failures. Overall, late stage clinical trials have highlighted very few molecules that could potentially replace current treatments during the forecast period.
Key Market Movements:
- Market experts suggest that a family history of Alzheimer’s increases the risk of disease development by 7.5 times
- The incidence and prevalence of Alzheimer’s disease doubles every five years after age 65 years
- Currently population of developed countries is at high risk of Alzheimer due to increasing geriatric population
- In developing countries from Asia Pacific and Latin America the awareness related to age-specific diseases such as dementia or Alzheimer is increasing
Alzheimer’s Therapeutics Market: Market Dynamics and Outlook
3.1 Alzheimer’s Therapeutics Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Alzheimer’s Therapeutics Market, 2015 (Value %)
Chapter 4 Global Alzheimer’s Therapeutics Market, By Drugs
4.1 Preface
4.2 Memantine Hydrochloride
4.3 Donepezil Hydrochloride
4.4 Rivastigmine
4.5 Galantamine Hydrobromide
4.6 Pipeline Analysis
4.6.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.6.1.1 ENA713
4.6.1.2 Flutemetamol (18F)
4.6.1.3 LY450139
4.6.1.4 Dimebon
4.6.1.5 Aripiprazole/ BMS-337039
4.6.2 Tabular Representation of Phase II and I Drugs
Chapter 5 Global Alzheimer’s Therapeutics Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (RoW)
5.5.1 Latin America
5.5.2 Middle East and Africa
“ Alzheimer’s Therapeutics Market” is a new report by us that explains how companies‘ acquisition expenditures, media spend, business strategies, marketing and sales strategies and practices, and business plan are set to change in 2017-2018. This paper gives you access to the category-level spending forecasts, business challenges, budgets, supplier selection criteria, the current size of the marketing and promotion budgets and investment opportunities for senior-level officials. The report also identifies the expected growth of buyers and suppliers, capital expenditure, staff hiring, M and A, and e-procurement. This report not only gives access to the views and strategies of business decision makers and rivals but also examines their actions circling business priorities. The report also provides access to information categorized by company type and sizes, region,
Introduction and Landscape
Why was the report written?
This report is the result of an extensive survey drawn from Our Research’s elite panel of leading global senior level executives from enterprises such as such as medical devices, mining, packaging, power, oil, and gas, food and beverage, airports and pharmaceutical. The report covers key topics such as appropriation behaviors and strategies, the current size of the marketing and advertising budgets. Besides the report also recognizes the threats and possibilities, economic outlook trends, media channel spending outlooks, M and A expectations, marketing agency selection models, media budgets, business challenges and confidence among senior-level executives across various industries. Most secondary research papers are based on general industry drivers and do not understand the industry officials‘ attitude and changing behaviors, creating a gap in showing the business opportunity of the industry. In an effort to bridge this gap, Our Research created this primary-research based report by selecting the opinions of various stakeholders in the value-chain of the industry
This report offers:
- Analysis of several products, and regions that would provide the clear understanding of the ongoing and future trends in the global Alzheimer’s Therapeutics market
- Assessment of market dynamics such as drivers, restraints, and opportunities prevalent in the market
- Quantitative assessment of the current market size and future estimations for the period from 2016 to 2026, along with CAGRs for the period from 2018 to 2026
- Company profiles that will highlight key information about the imperative players operating in the global Alzheimer’s Therapeutics devices market
Here you can get an updated sample on this report: https://www.credenceresearch.com/sample-request/57811
About us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in the Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
Contact Us:
Credence Research Inc.
105 N 1st ST #429
SAN JOSE
CA 95103
United States
Email: